Phaseline

Companies › Crossbow Therapeutics

Crossbow Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CBX-250–Phase 1High-risk Myelodysplastic SyndromeJan 2027
CBX-663–Phase 1Advanced Solid TumorsJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06994676CBX-250Phase 1High-risk Myelodysplastic SyndromeOncologyJan 2027
NCT07779798CBX-663Phase 1Advanced Solid TumorsOncologyJan 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.